Prospective Grant of Exclusive License: Start-Up Commercial License for the Development of Fenoterol and Fenoterol Analogues for the Treatment of Brain, Liver, and Pancreatic Cancers and Congestive Heart Failure, 37234 [2013-14645]
Download as PDF
<![CDATA[
37234
Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Start-Up Commercial License
for the Development of Fenoterol and
Fenoterol Analogues for the Treatment
of Brain, Liver, and Pancreatic Cancers
and Congestive Heart Failure
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant to Mitchell
Woods Pharmaceuticals, LLC, of an
exclusive commercialization license to
practice the inventions embodied in the
following U.S. Patent Applications (and
all continuing applications and foreign
counterparts): Serial No. 61/651,961,
filed May 25, 2012, entitled, ‘‘Methods
of Regulating Cannabinoid Receptor
Activity-related Disorders and Diseases’’
[HHS Reference E–139–2012/0–US–1];
Serial No. 61/789,629, filed March 15,
2013, entitled, ‘‘Methods of Regulating
Cannabinoid Receptor Activity-related
Disorders and Diseases’’ [HHS Reference
E–139–2012/1–US–1]; Serial No. 61/
312,642, filed March 10, 2010, entitled,
‘‘The Use of Fenoterol and Fenoterol
Analogues in the Treatment of
Glioblastomas and Astrocytomas’’ [HHS
Reference E–013–2010/0–US–01]; Serial
No. 60/837,161, filed August 10, 2006,
entitled, ‘‘Preparation of R,R-Fenoterol
and R,R-Fenoterol Analogues and Their
Use in Congestive Heart Failure’’ [HHS
Reference E–205–2006/0–US–1]; and
Serial No. 60/927,825, filed May 3,
2007, entitled ‘‘Preparation of R,RFenoterol and R,R-Fenoterol Analogues
and Their Use in Congestive Heart
Failure’’ [HHS Reference E–205–2006/
1–US–1]. The patent rights in these
inventions have been assigned or
exclusively licensed to the Government
of the United States of America.
The prospective exclusive
commercialization license territory may
be worldwide, and the scope may be
limited to the following two fields of
use:
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Licensed Field of Use I: An exclusive
license to the Patent Rights for research,
development, manufacture, distribution, sale,
and use in humans for the treatment of brain
cancer, liver cancer, or pancreatic cancer
within the Licensed Territory of (R,R′)-4′methoxy-1-napthylfenoterol (MNF), (R,S′)-4′methoxy-1-napthylfenoterol, (R,R′)ethylMNF, (R,R′)-napthylfenoterol, (R,S′)
VerDate Mar<15>2010
17:01 Jun 19, 2013
Jkt 229001
napthylfenoterol, (R,R′)-ethylnapthylfenoterol, and (R,R′)-4′-amino-1napthylfenoterol, (R,R′)-4′-hydroxy-1napthylfenoterol, (R,R′)-4-methoxyethylfenoterol, (R,R′)-methoxyfenoterol,
(R,R′)-ethylfenoterol, (R,R′)-fenoterol; and
their respective stereoisomers.
Licensed Field of Use II: An exclusive
license to the Patent Rights for research,
development, and manufacture of Licensed
Products incorporating the Licensed Patent
Rights; and distribution, sale, and use of such
Licensed Products in humans for the
treatment of congestive heart failure within
the Licensed Territory.
Dated; June 14, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
& Transfer, Office of Technology Transfer,
National Institutes of Health.
Only written comments or
applications for a license (or both)
which are received by the NIH Office of
Technology Transfer on or before July 5,
2013 will be considered.
Notice of Invitation; Coal Exploration
License Application NDM 105349, ND
DATES:
Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive evaluation
option license should be directed to:
Patrick McCue, Ph.D., Licensing and
Patenting Manager, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5560; Facsimile:
(301) 402–0220; Email:
mccuepat@mail.nih.gov.
ADDRESSES:
This
invention concerns the use of fenoterol
analogues in treatments for tumors
expressing a cannabinoid receptor, and
in treatments for congestive heart
failure.
The prospective exclusive
commercialization license is being
considered under the small business
initiative launched on 1 October 2011,
and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR
404.7. The prospective exclusive
commercialization license may be
granted unless the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.7
within fifteen (15) days from the date of
this published notice.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
commercialization license. Comments
and objections submitted to this notice
will not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
[FR Doc. 2013–14645 Filed 6–19–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Bureau of Land Management
[LLMT921000–13–L13200000–EL0000–P;
NDM 105349]
Bureau of Land Management,
Interior.
ACTION: Notice.
AGENCY:
Members of the public are
invited to participate with BNI Coal Ltd.
on a pro rata cost sharing basis in a
program for the exploration of coal
deposits owned by the United States of
America in lands located in Oliver
County, North Dakota, encompassing
480 acres.
DATES: Any party seeking to participate
in this exploration program must send
written notice to both the Bureau of
Land Management (BLM) and BNI Coal
Ltd. as provided in the ADDRESSES
section below no later than July 22,
2013 or 10 calendar days after the last
publication of this Notice in the
Bismarck Tribune newspaper,
whichever is later. This Notice will be
published once a week for 2 consecutive
weeks in the Bismarck Tribune,
Bismarck, North Dakota. Such written
notice must refer to serial number NDM
105349.
ADDRESSES: The proposed exploration
license and plan are available for review
from 9 a.m. to 4 p.m., Monday through
Friday, in the public room at the BLM
Montana State Office, 5001 Southgate
Drive, Billings, Montana.
A written notice to participate in the
exploration license should be sent to the
State Director, BLM Montana State
Office, 5001 Southgate Drive, Billings,
MT 59101–4669 and BNI Coal, 2360
35th Ave. SW., Center, ND 58530.
FOR FURTHER INFORMATION CONTACT:
Anne Allen by telephone at 406–896–
5082 or by email at amallen@blm.gov; or
Kym Dowdle by telephone at 406–896–
5046 or by email at kdowdle@blm.gov.
Persons who use a telecommunications
device for the deaf (TDD) may call the
Federal Information Relay Service
(FIRS) at 1–800–877–8339 to contact the
above individual during normal
business hours. The FIRS is available 24
SUMMARY:
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 78, Number 119 (Thursday, June 20, 2013)]
[Notices]
[Page 37234]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14645]
[[Page 37234]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Start-Up Commercial
License for the Development of Fenoterol and Fenoterol Analogues for
the Treatment of Brain, Liver, and Pancreatic Cancers and Congestive
Heart Failure
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR Part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant to
Mitchell Woods Pharmaceuticals, LLC, of an exclusive commercialization
license to practice the inventions embodied in the following U.S.
Patent Applications (and all continuing applications and foreign
counterparts): Serial No. 61/651,961, filed May 25, 2012, entitled,
``Methods of Regulating Cannabinoid Receptor Activity-related Disorders
and Diseases'' [HHS Reference E-139-2012/0-US-1]; Serial No. 61/
789,629, filed March 15, 2013, entitled, ``Methods of Regulating
Cannabinoid Receptor Activity-related Disorders and Diseases'' [HHS
Reference E-139-2012/1-US-1]; Serial No. 61/312,642, filed March 10,
2010, entitled, ``The Use of Fenoterol and Fenoterol Analogues in the
Treatment of Glioblastomas and Astrocytomas'' [HHS Reference E-013-
2010/0-US-01]; Serial No. 60/837,161, filed August 10, 2006, entitled,
``Preparation of R,R-Fenoterol and R,R-Fenoterol Analogues and Their
Use in Congestive Heart Failure'' [HHS Reference E-205-2006/0-US-1];
and Serial No. 60/927,825, filed May 3, 2007, entitled ``Preparation of
R,R-Fenoterol and R,R-Fenoterol Analogues and Their Use in Congestive
Heart Failure'' [HHS Reference E-205-2006/1-US-1]. The patent rights in
these inventions have been assigned or exclusively licensed to the
Government of the United States of America.
The prospective exclusive commercialization license territory may
be worldwide, and the scope may be limited to the following two fields
of use:
Licensed Field of Use I: An exclusive license to the Patent
Rights for research, development, manufacture, distribution, sale,
and use in humans for the treatment of brain cancer, liver cancer,
or pancreatic cancer within the Licensed Territory of (R,R')-4'-
methoxy-1-napthylfenoterol (MNF), (R,S')-4'-methoxy-1-
napthylfenoterol, (R,R')-ethylMNF, (R,R')-napthylfenoterol, (R,S')
napthylfenoterol, (R,R')-ethyl-napthylfenoterol, and (R,R')-4'-
amino-1-napthylfenoterol, (R,R')-4'-hydroxy-1-napthylfenoterol,
(R,R')-4-methoxy-ethylfenoterol, (R,R')-methoxyfenoterol, (R,R')-
ethylfenoterol, (R,R')-fenoterol; and their respective
stereoisomers.
Licensed Field of Use II: An exclusive license to the Patent
Rights for research, development, and manufacture of Licensed
Products incorporating the Licensed Patent Rights; and distribution,
sale, and use of such Licensed Products in humans for the treatment
of congestive heart failure within the Licensed Territory.
DATES: Only written comments or applications for a license (or both)
which are received by the NIH Office of Technology Transfer on or
before July 5, 2013 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
evaluation option license should be directed to: Patrick McCue, Ph.D.,
Licensing and Patenting Manager, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-5560; Facsimile: (301)
402-0220; Email: mccuepat@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This invention concerns the use of fenoterol
analogues in treatments for tumors expressing a cannabinoid receptor,
and in treatments for congestive heart failure.
The prospective exclusive commercialization license is being
considered under the small business initiative launched on 1 October
2011, and will comply with the terms and conditions of 35 U.S.C. 209
and 37 CFR 404.7. The prospective exclusive commercialization license
may be granted unless the NIH receives written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7 within
fifteen (15) days from the date of this published notice.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive commercialization license. Comments and
objections submitted to this notice will not be made available for
public inspection and, to the extent permitted by law, will not be
released under the Freedom of Information Act, 5 U.S.C. 552.
Dated; June 14, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-14645 Filed 6-19-13; 8:45 am]
BILLING CODE 4140-01-P
